AUS
NZ
UK
CA
USA
IND
On July 23, 2026, Frederic J. Winssinger, a director at USANA Health Sciences Inc., acquired 1,632 shares of common stock through the vesting of restricted stock units, as detailed in a regulatory filing dated July 27, 2026. This transaction increases Winssinger's direct beneficial ownership to 9,733 shares. The equity acquisition reflects a routine compensation event aligned with the company’s board member and executive pay structure.
Key Points
- NYSE: USNA
- Director Frederic J. Winssinger acquired 1,632 shares via restricted stock unit vesting on July 23, 2026
- Post-transaction, Winssinger holds 9,733 shares in direct beneficial ownership
- RSUs vest in four equal quarterly installments through April 22, 2027
Director Frederic J. Winssinger's Equity Acquisition Through RSU Vesting
Frederic J. Winssinger, serving on the board of USANA Health Sciences Inc., completed a transaction on July 23, 2026, acquiring 1,632 shares of the company’s common stock via restricted stock unit (RSU) vesting. This equity compensation method is standard for board members and senior executives. The transaction was officially reported in a Securities and Exchange Commission filing on July 27, 2026.
The filing confirms Winssinger’s direct beneficial ownership of these shares, bringing his total holdings to 9,733 shares. Each vested RSU converts into one share of USANA common stock, as outlined in the filing’s explanatory section.
RSU Vesting Timeline and Future Share Releases
The RSUs involved are set to vest in four equal quarterly installments over roughly one year. The vesting dates include July 23, 2026 (initial 25%), followed by October 22, 2026, January 21, 2027, and April 22, 2027, each releasing an additional 25% of the units. This staggered vesting aligns director and executive interests with long-term company performance and shareholder value.
The total RSU grant amounts to 1,632 shares, with the first quarter vested on July 23, 2026. Winssinger is scheduled to receive approximately 408 shares on each of the remaining three vesting dates, assuming no changes to the vesting schedule. The filing does not indicate any conditions that could impede future vesting.
Winssinger’s Board Role and Stock Ownership Details
The regulatory filing identifies Frederic J. Winssinger as a director of USANA Health Sciences Inc., as indicated by the checked "Director" box. Equity-based compensation is a common component of director remuneration in publicly traded companies, designed to align their interests with shareholders. Winssinger’s address is listed as Phoenix, Arizona; however, no specific board committee roles or duties are detailed.
Following the July 23, 2026 vesting, Winssinger’s direct beneficial ownership totals 9,733 shares, held outright rather than through any trust or entity. Public information does not reveal any immediate impact on the company’s share price. Investors tracking insider transactions may observe future share acquisitions or sales as the remaining RSUs vest.
Understanding RSUs as an Equity Compensation Tool
Restricted stock units are a prevalent equity compensation vehicle in public companies. Unlike stock options, RSUs automatically convert into shares upon vesting without requiring payment from the recipient, provided the individual remains employed or continues serving in their role. Winssinger’s RSU grant follows a quarterly vesting schedule, a common strategy to distribute compensation value and tax liabilities over time.
Each RSU represents a contingent right to one share of USANA common stock. Upon each vesting date, this right becomes vested and shares are issued to Winssinger. The filing’s zero-dollar price notation reflects that RSUs do not have an exercise price, differing fundamentally from stock options which require payment to exercise.
Regulatory Filing and Compliance Details
The disclosure was filed on July 27, 2026, four days after the transaction on July 23, 2026. Joshua Foukas, acting as attorney-in-fact for Winssinger, signed the filing, a permitted arrangement under SEC rules allowing authorized agents to submit reports. The filing was submitted as a single reporting person form, confirming Winssinger as the sole reporter for this transaction.
This disclosure complies with Section 16(a) of the Securities Exchange Act of 1934, mandating officers, directors, and 10% beneficial owners to report ownership changes. The SEC’s standardized forms promote transparent and consistent insider transaction reporting. Market participants use these filings to gauge insider confidence and investment activity.
Company Overview and Investor Implications
USANA Health Sciences Inc. is a global network marketing company producing nutritional supplements, weight management products, and personal care items. Operating through independent distributors worldwide, the company compensates directors like Winssinger with a mix of cash and equity-based pay.
Investors monitoring USANA insider transactions typically view RSU vesting as routine compensation rather than market sentiment indicators. The quarterly vesting schedule means Winssinger’s share count will increase incrementally over the next several months, assuming his directorship continues. The disclosure enhances transparency regarding insider equity holdings and compensation timing.
No Indications of Adverse Conditions or Vesting Contingencies
The filing reveals no material adverse developments, contingencies, or unusual factors affecting the RSU grant or vesting schedule. It represents a standard equity compensation event with no commentary on market conditions or company performance affecting vesting or Winssinger’s board service.
No statements were made regarding Winssinger’s views on USANA’s valuation or future outlook. As with all insider filings, this report serves as a factual record of ownership changes, not an endorsement or critique of share price. The RSU vesting is a predetermined event, distinct from voluntary market trades that might reflect insider sentiment.
Context Within USANA’s Insider Activity Trends
While this filing does not provide historical insider transaction data, RSU vesting is a common recurring event in public companies. The report documents one quarterly vesting tranche from a prior RSU grant to Winssinger. Investors seeking comprehensive insights into insider compensation or trading patterns at USANA should review multiple filings over time.
The RSU grant’s structure—equal quarterly vesting over one year—aligns with typical director compensation practices. The filing does not specify whether this is Winssinger’s initial equity grant or part of multiple tranches. For detailed information on insider pay policies, board compensation, and vesting history, investors should consult USANA’s proxy statements and governance disclosures.
